NASDAQ: LNSRLensar Inc Stock
$3.04+0.03 (+1%)
Updated Jun 2, 2023
LNSR Price
$3.04
Fair Value Price
$4.48
Market Cap
$33.75M
52 Week Low
$1.90
52 Week High
$7.55
P/E
-1.8x
P/B
0.86x
P/S
0.78x
PEG
N/A
Dividend Yield
N/A
Revenue
$34.27M
Earnings
-$17.51M
Gross Margin
57.1%
Operating Margin
-51.1%
Profit Margin
-51.1%
Debt to Equity
0.32
Operating Cash Flow
-$19M
Beta
0.36
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LNSR Overview
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its LENSAR Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company was incorporated in 2004 and is headquartered in Orlando, Florida.
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LNSR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LNSR ($3.04) is undervalued by 32.21% relative to our estimate of its Fair Value price of $4.48 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LNSR ($3.04) is significantly undervalued by 32.21% relative to our estimate of its Fair Value price of $4.48 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LNSR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LNSR due diligence checks available for Premium users.
Be the first to know about important LNSR news, forecast changes, insider trades & much more!
LNSR News
Valuation
LNSR fair value
Fair Value of LNSR stock based on Discounted Cash Flow (DCF)
Price
$3.04
Fair Value
$4.48
Undervalued by
32.21%
LNSR ($3.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LNSR ($3.04) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LNSR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LNSR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.8x
Industry
780.69x
Market
52.69x
LNSR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
3.96x
LNSR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LNSR's financial health
Profit margin
Revenue
$8.3M
Net Income
-$4.3M
Profit Margin
-51.8%
LNSR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LNSR's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$52.0M
Liabilities
$12.5M
Debt to equity
0.32
LNSR's short-term assets ($29.98M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LNSR's short-term assets ($29.98M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LNSR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.7M
Investing
-$8.0k
Financing
$0.0
LNSR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LNSR vs Medical Device Stocks
Lensar Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.